Novavax price target raised to $10 from $2.25 at B. Riley FBR B. Riley FBR analyst George Zavoico raised Novavax's price target to $10 from $2.25 and reiterated a Buy rating after the company provided further details about the FDA's informational analysis of Prepare, an ongoing Phase III trial of an RSV F vaccine for maternal immunization to protect newborn infants.